innoVitro GmbH is a Contract Research Organisation providing human-based cardiac risk and efficacy screening services for Pharma, Biotech and Academia worldwide. Each service is custom-tailored by an expert team in close cooperation with the client and carried out as end-to-end study report in less than 6 weeks.

Screening parameters encompass structural and functional endpoints of human iPSC-derived cardiomyocytes, analysed with a high throughput 96-well hybrid system. Drug-induced changes of healthy or diseased cells can be assessed regarding cellular and electrophysiological properties (CardioExcyte Module) as well as changes in contractility (FLEXcyte 96 Module). Here, adult-like contractile force analysis is provided through flexible membranes mimicking in vivo conditions of the human heart.